Studying nerve-muscle organoids for refractory myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study uses lab-grown mini muscle-nerve cells (organoids) to better understand severe, hard-to-treat myasthenia gravis. It may help researchers find new treatment options for people with the AChR antibody type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed diagnosis of generalized myasthenia gravis with positive AChR antibodies.
- You have had your disease and treatment tracked for at least 12 months (or are newly diagnosed).
- You agree to sign a consent form to take part (and to allow use of stored samples if applicable).
- You do not have other autoimmune disorders or neuromuscular diseases, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses wearable sensors to track symptoms of myasthenia gravis in daily life. The goal is to see if these devices can better monitor how the disease changes over time.
This study looks at how the thymus gland and certain antibodies relate to myasthenia gravis, a condition that causes muscle weakness. It may help doctors understand the disease better and could lead to improved treatments.
This study follows people with suspected or confirmed myasthenia gravis (a condition that causes muscle weakness that gets worse with use). It uses several specialized nerve and antibody tests to make a more precise diagnosis and tracks you over time to see how well these methods work.
This trial tests an investigational drug called SHR-2173, given as an injection, for people with generalized myasthenia gravis. It aims to see if the drug can improve muscle strength and daily function.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This trial tests an experimental drug (EA5) injected under the skin or into a vein for people with a specific form of myasthenia gravis (caused by AChR antibodies). The goal is to find the safest dose and see how well it may reduce muscle weakness.
Hear when a new Myasthenia Gravis Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.